February 15, 2017 / 12:56 AM / in 7 months

BRIEF-Theratechnologies announces new data from the pivotal phase III trial of Ibalizumab

Feb 14 (Reuters) - Theratechnologies Inc:

* Theratechnologies announces new data from the pivotal phase III trial of HIV monoclonal antibody and long-acting investigational antiretroviral Ibalizumab

* Theratechnologies - patients enrolled in phase III trial experienced significant decrease in viral load after receiving single loading dose of Ibalizumab 2,000 mg

* Says no notable trends in laboratory abnormalities were observed.

* Says safety results in this phase III trial are consistent with ones previously observed in phase IIB trial. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below